21 / 38
J u n e 1 1 - 1 3 , 2 0 1 8 | D u b l i n , I r e l a n d
allied
academies
Page 44
Note:
CANCER STEM CELLS AND
ONCOLOGY RESEARCH
11
th
International Conference on
Journal of Medical Oncology and Therapeutics
|
Volume 3
Jie Ni et al., J Med Oncl Ther 2018, Volume 3
CD44 VARIANT 6 (CD44v6) AS A
CANCER STEM CELL BIOMARKER IN
PROSTATE CANCER PROGRESSION
AND CHEMO-/RADIO-RESISTANCE
Jie Ni
1, 2
, Paul Cozzi
1, 2
, Julia Beretov
1, 2
, Joseph Bucci
1, 2
,
Peter Graham
1, 2
and
Yong Li
1, 2
1
St. George Hospital, Kogarah, Australia
2
University of New South Wales, Australia
P
rostate cancer (CaP) is the most common cancer in men in western
countries, accounting for estimated 161,360 new cases and 26,730
deaths in the US in 2017. Chemo-/radio-resistance is an important
reason for CaP progression and metastasis. CD44 is a well-documented
cancer stem cell (CSC) biomarker, and one of its variants, CD44 variant 6
(CD44v6) is closely associated with aggressive behaviour and correlates
with poor prognosis in a variety of human cancers. Our previous study has
demonstrated increased expressions of CD44v6 in metastatic CaP cell
lines and human CaP tissues which was associated with CaP progression
and chemo-/radio-resistance
in vitro
. However, the role of CD44v6 in CaP
progression and therapeutic resistance
in vivo
is still uncertain. The aim
of this study was to investigate the role of CD44v6 in CaP development
and chemo-/radio-resistance as well as underlying pathways
in vivo
, and
find whether it is a suitable therapeutic target for CaP therapy.
Jie Ni is a Scientific Officer and Hospital Scien-
tist in Department of Radiation Oncology, Can-
cer Services at St George Hospital, Sydney and
Conjoint Lecturer in St George and Sutherland
Clinical School, Faculty of Medicine at UNSW
Sydney, Australia. He obtained his M.D. and B.A.
degrees from China in 2011 as an outstanding
graduate and national scholarship awardee
and completed his PhD in Faculty of Medicine
at UNSW Sydney in 2015. During his PhD can-
didature he was awarded Prostate and Breast
Cancer Foundation Scholarship from 2012-
2015, and Outstanding Self-Financed Students
Abroad Award of China in 2013. The nature of
the degrees has equipped him with a strong
background of medical practice, and has in-
volved a great deal of independent basic, trans-
lational and clinical research. He has 19 publi-
cations (6 as the first-author, 2 invited reviews)
on peer-reviewed journals on novel therapeutic
modalities and targets on prostate, ovarian, cer-
vical and breast cancers. His publications have
been cited more than 480 times with a Scopus
h-index of 11 and he constantly publishes in
top-ranking journals including Theranostics, On-
cotarget, Cell Death and Disease, Prostate, and
Cancer Metastasis Reviews. He has been an
executive committee member of the Australian
Association for Chinese Biomedical Scientists
since 2011, a member of American Association
for Cancer Research since 2012, European As-
sociation for Cancer Research since 2017 and
European Society for Medical Oncology since
2017. He is currently co-supervising and men-
toring PhD students, ILP students and visiting
research fellows, and has served as a reviewer
for numerous journals and universities.
jie.ni@health.nsw.gov.auBIOGRAPHY